Viewing Study NCT00524303

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:49 PM
Ignite Modification Date: 2025-12-29 @ 5:08 PM
Study NCT ID: NCT00524303
Status: COMPLETED
Last Update Posted: 2016-11-11
First Post: 2007-08-31
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms, Breast View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ErbB2 Overexpressing View
None ErbB2 Positive View
None Lapatinib View
None Invasive Breast Cancer View